Q2FY26 Quarterly Result Announced for Thyrocare Technologies Ltd.

Q2FY26 Quarterly Result Announced for Thyrocare Technologies Ltd. -

Healthcare Services company Thyrocare Technologies announced Q2FY26 results Consolidated revenue of Rs 216.53 crore, registering a strong 22% YoY growth. EBITDA rose sharply by 49% YoY to Rs 75.36 crore. EBITDA margin of 33% for Q2FY26. Profit After Tax surged 82% YoY to Rs 47.90 crore. PAT Margin: 22% for Q2FY26. Board of Directors has declared an interim dividend of Rs 7 per equity share (of Rs 10 face value each, pre-bonus) with 24-October-2025 as the record date, and approved a bonus issue in the ratio of 2:1, subject to statutory, regulatory, and shareholder approval. Rahul Guha, MD & CEO, Thyrocare Technologies, said: “We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and valuedriven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India” Sunil Kotak (Founder of SHUBH CONSULTANCY - SEBI Registered Research Analyst| INH000015826) Disclaimer: Investments are subject to market risk please read relevant documents before investing. Past performance will not guarantee the future results. My self/may associates do not own any stock recommended here. Me/My associates/My relatives do not have any conflict of Interest in the recommended stock. Me/My associates/My relatives have not received any compensation from the Company in last 12 months. Me/My associates/My relatives do not have holding above 1% in the stock recommended. This is for Intended Recipient only. Advisable to assume that we have recommended this one to our clients. This is not a buy/sell recommendation.